Sale!

5-Flurouracil 5-FU Toxicity and Chemotherapeutic Response DPYD Variants Test

Name: 5-Flurouracil 5-FU Toxicity and Chemotherapeutic Response DPYD Variants Test
SKU: TEST-5527
Price: 1260 AED
Availability: InStock

Original price was: 1,400 د.إ.Current price is: 1,260 د.إ.

-10%

The “5-Fluorouracil (5-FU) Toxicity and Chemotherapeutic Response DPYD Variants Test” is a specialized diagnostic tool offered by DNA Labs UAE, priced at 1260 AED. This test is designed to identify genetic variants in the DPYD gene, which plays a crucial role in the metabolism of 5-FU, a common chemotherapeutic agent used in the treatment of various cancers, including colorectal, breast, and stomach cancers.

5-FU works by inhibiting DNA synthesis in cancer cells, thereby preventing their growth and proliferation. However, its effectiveness and the risk of toxicity vary significantly among individuals, largely due to genetic differences in the DPYD gene. Certain variants in the DPYD gene can lead to reduced or absent activity of the dihydropyrimidine dehydrogenase (DPD) enzyme, which is responsible for breaking down 5-FU. Individuals with these genetic variations may experience severe or life-threatening toxicity when treated with standard doses of 5-FU, including neutropenia, neurotoxicity, severe diarrhea, and mucositis.

The DPYD Variants Test aims to identify patients who are at an increased risk of experiencing adverse reactions to 5-FU chemotherapy. By analyzing specific genetic variants in the DPYD gene, healthcare providers can tailor chemotherapy treatments to the individual’s genetic makeup, optimizing therapeutic outcomes while minimizing the risk of toxicity. This personalized approach to cancer treatment enhances the efficacy of 5-FU therapy and improves patient safety.

In summary, the 5-FU Toxicity and Chemotherapeutic Response DPYD Variants Test offered by DNA Labs UAE is a crucial tool in the field of personalized medicine, enabling clinicians to make informed decisions regarding 5-FU chemotherapy regimens based on a patient’s genetic predisposition to drug toxicity. At a cost of 1260 AED, this test represents a valuable investment in optimizing cancer treatment and patient care.

Description

5-Flurouracil 5-FU Toxicity and Chemotherapeutic Response DPYD variants Test

Test Name: 5-Flurouracil 5-FU Toxicity and Chemotherapeutic Response DPYD variants Test

Components: EDTA Vacutainer (2ml)

Price: 1260.0 AED

Sample Condition: Peripheral blood

Report Delivery: 3-4 days

Method: Sanger Sequencing

Test type: Genetics

Doctor: Gynecologist

Test Department:

Pre Test Information: 5-Flurouracil (5-FU) Toxicity and Chemotherapeutic Response (DPYD variants) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details:

5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for the treatment of various cancers, including colorectal, breast, and head and neck cancers. However, some individuals may experience toxicity when treated with 5-FU, leading to adverse effects and potentially life-threatening complications.

One of the factors that contribute to 5-FU toxicity is the presence of genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene. DPYD is responsible for the metabolism of 5-FU, converting it into an inactive form. Variants in the DPYD gene can lead to reduced or absent enzyme activity, resulting in decreased metabolism of 5-FU and increased drug exposure.

Patients with DPYD variants are at a higher risk of developing severe toxicity when treated with 5-FU. The most common toxicities observed include severe myelosuppression (bone marrow suppression), gastrointestinal toxicity (such as severe diarrhea and mucositis), and hand-foot syndrome (painful redness, swelling, and peeling of the skin on the palms of the hands and soles of the feet).

Identifying DPYD variants in patients before initiating 5-FU treatment can help to personalize chemotherapy dosing and reduce the risk of toxicity. Genetic testing can be done to detect DPYD variants, and if a patient is found to have a variant associated with increased risk, alternative treatment options or dose adjustments can be considered.

In addition to genetic factors, other factors such as age, kidney function, and concomitant medications can also influence the risk of 5-FU toxicity. Therefore, a comprehensive assessment of these factors is necessary to optimize treatment and minimize adverse effects.

It is important to note that not all patients with DPYD variants will experience severe toxicity, and some may tolerate standard doses of 5-FU without complications. Therefore, individualized treatment decisions should be made based on the patient’s overall health status, treatment goals, and potential benefits versus risks.

In conclusion, DPYD variants play a significant role in 5-FU toxicity, and identifying these variants can help personalize chemotherapy dosing and reduce the risk of severe adverse effects. Genetic testing and a comprehensive assessment of other risk factors are necessary to optimize treatment and improve patient outcomes.

Test Name	5-Flurouracil 5-FU Toxicity and Chemotherapeutic Response DPYD variants Test
Components	EDTA Vacutainer (2ml)
Price	1260.0 AED
Sample Condition	Peripheral blood
Report Delivery	3-4 days
Method	Sanger Sequencing
Test type	Genetics
Doctor	Gynecologist
Test Department:
Pre Test Information	5-Flurouracil (5-FU) Toxicity and Chemotherapeutic Response (DPYD variants) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details	5-Fluorouracil (5-FU) is a commonly used chemotherapeutic agent for the treatment of various cancers, including colorectal, breast, and head and neck cancers. However, some individuals may experience toxicity when treated with 5-FU, leading to adverse effects and potentially life-threatening complications. One of the factors that contribute to 5-FU toxicity is the presence of genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene. DPYD is responsible for the metabolism of 5-FU, converting it into an inactive form. Variants in the DPYD gene can lead to reduced or absent enzyme activity, resulting in decreased metabolism of 5-FU and increased drug exposure. Patients with DPYD variants are at a higher risk of developing severe toxicity when treated with 5-FU. The most common toxicities observed include severe myelosuppression (bone marrow suppression), gastrointestinal toxicity (such as severe diarrhea and mucositis), and hand-foot syndrome (painful redness, swelling, and peeling of the skin on the palms of the hands and soles of the feet). Identifying DPYD variants in patients before initiating 5-FU treatment can help to personalize chemotherapy dosing and reduce the risk of toxicity. Genetic testing can be done to detect DPYD variants, and if a patient is found to have a variant associated with increased risk, alternative treatment options or dose adjustments can be considered. In addition to genetic factors, other factors such as age, kidney function, and concomitant medications can also influence the risk of 5-FU toxicity. Therefore, a comprehensive assessment of these factors is necessary to optimize treatment and minimize adverse effects. It is important to note that not all patients with DPYD variants will experience severe toxicity, and some may tolerate standard doses of 5-FU without complications. Therefore, individualized treatment decisions should be made based on the patient’s overall health status, treatment goals, and potential benefits versus risks. In conclusion, DPYD variants play a significant role in 5-FU toxicity, and identifying these variants can help personalize chemotherapy dosing and reduce the risk of severe adverse effects. Genetic testing and a comprehensive assessment of other risk factors are necessary to optimize treatment and improve patient outcomes.